ImmunoPrecise Antibodies Ltd
IPA
Get informed when a big investor buys or sells
+ FollowMarket Cap$74.77M
Close$
Share Statistics
| Market cap | $74.77 Million |
|---|---|
| Enterprise Value | $65.09 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.91 |
| Beta | 0.49 |
| Outstanding Shares | 46,515,653 |
Return
| Return on Equity | -81.55% |
|---|---|
| Return on Assets | -52.72% |
| Return on Invested Capital | -68.91% |
Valuation & Multiples
| P/E Ratio | -8.33 |
|---|---|
| PEG | 10.16 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 3.54 |
| Enterprise Value to EBIT | -5.22 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.3 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 12, 2026
EPS Estimate
$-0.04
Average shareholder expectationRevenue Estimate
$5.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.02%▼ 12.06% |
|---|---|
| Total Invested | $17,500▼ 99.59% |
| Investors Holding | 1▼ 25.00% |
ESG Score
No data
About ImmunoPrecise Antibodies Ltd
2,021 employeesIPA is an innovation-driven, technology platform company that supports its pharmaceutical and biotechnology company partners in their quest to discover and develop novel, therapeutic antibodies against all classes of disease targets. The...